logo
Is in-depth and expensive blood work worth it?

Is in-depth and expensive blood work worth it?

Globe and Mail11-05-2025

A number of new startups suggest looking at your blood for improvements in energy, mood, and even lifespan. Growing up, the only time I'd have blood work was if something was wrong. Doctors would run tests to check levels relating to negative symptoms. Blood counts to check for infections or problems with the immune symptoms. A metabolic panel to examine the kidneys. If my levels fell within a desired range, no action was taken.
But increasingly, folks looking to optimize their health are taking a new approach to blood work, seeking out the tests and reading them like tea leaves. Results aren't just to indicate sickness or stressors. They're supposedly a gateway into more energy, better sex and a happier, longer, life.
That's the selling point for a number of companies offering full blood-work panels outside of regular doctor visits. Brands like Life Labs, The Bespoke Wellness Group and Inside Tracker tout the benefits of personal analytics based on blood work. The detailed information gives you a more complete understanding of both how your body works now and how it might work better.
It's info that comes with costs and risks. Packages including comprehensive testing, pages explaining that data, and personalized follow-up plans run about $600. While companies have privacy policies in place, handing over sensitive information is never 100-per-cent safe, as shown with the recent bankruptcy of 23andMe.
Still, blood work offers factual information about what's going on in your body. Changes to your diet, workout and supplement routines can be shown in the results, offering empirical feedback when health matters can often feel like guesswork. Recently, I underwent a comprehensive blood-work panel from Canadian startup NiaHealth. The hope was that by checking my levels and crunching the numbers, I'd be able to make some changes.
The past few months, I've been feeling exhausted. I've been having trouble completing workouts at the gym. I'm foggy during meetings, and getting up in the morning can feel like a herculean task. Nothing is wrong exactly, but things are not great. With continuing fatigue, I wanted to make sure something else wasn't going on with my health. Because I don't have a family doctor, blood work seemed like one of the best bets to do that.
'I encourage patients to get our blood work done on a semi-regular basis,' said Amanda Jaeger, a naturopathic doctor with Step Up Massage and Rehab.
Naturopaths are limited in what they can offer. Compared with a physician, their focus is generally around optimization rather than medical care. For Jaeger, the tests help zero in on the cause of certain problems and catch things that might not be obvious on a surface level.
'There are things that some people accept as normal − things like period cramps or fatigue − that don't necessarily have to be that way.'
Through her clinic, Jaeger is able to make recommendations for supplementation and lifestyle changes based on numbers in the blood work. Even if folks' biomarker levels are within 'normal' ranges, that can make meaningful impacts on patient's day to day.
'When it comes to reference ranges, there are some stark differences from the lowest to highest. … I'm trying to look for optimal functions rather than normal ranges.'
For my NiaHealth test, I chose a panel with fifty-plus biomarkers plus a testosterone add on. There was also a thirty-minute consultation with a nurse practitioner from their team to explain my results.
While a lot of startups in the blood-work space offer comprehensive biomarkers with their tests, Jaeger notes that most people can get by with less. A complete blood count, a comprehensive metabolic panel, a TSH screening for thyroid, vitamin D and inflammatory markers are cheaper tests or things that can be assigned through public health that give a great overview of what's happening with your body. Still, accessing those tests can be difficult from a walk-in clinic or if you don't have a primary doctor.
My blood work came in less than a week after my visit to a local clinic. During the half hour NiaHealth consultation, a nurse practitioner pointed to borderline cholesterol levels, iron levels above average and some vitamin deficiencies. The website's dashboard offered graphs and grades for my results that were easy to read.
Overall I was at a B+. Suggestions for my diet included trying fatty fish. Offers for exercise included breaking up my walks throughout the day and trying to jog. While I ranked a perfect score for my testosterone, my levels are on the lowest end of normal, and suboptimal, according to previous tests I'd done with InsideTracker.
The nurse practitioner with NiaHealth was kind and informative, but after walking through my levels, there was hardly time to address the fatigue that had jump-started the process. She suggested that to better understand the causes of elevated biomarkers tests would need to be done with my (non-existent) primary-care provider. Nonetheless, getting the blood work done was helpful in planning some next steps. And for some, that can be an absolute game changer.
For former bodybuilder and current fitness coach Dominic Kuza, checking blood work was key to getting lean and achieving physique goals both for himself and his clients. An out-of-pocket blood panel revealed unaddressed thyroid issues that were a major setback for his training, requiring medication and lifestyle changes to get on track. Based in America, his basic blood panel did not include testing for thyroid functions or hormones.
'Through my own blood work I've found things that were completely overlooked by doctors, but this was due to how basic of a panel that a physical with your doctor contains,' said Kuza.
'Blood work gives us information that allows us to see how our body is functioning internally and why someone might be having a hard time progressing in the direction they are hoping to.'
For everything a blood-work panel offers, costs and potential privacy issues are important to consider when deciding whether you'd like to move forward with the work. In the case of NIA Health, it has a privacy policy that says it will not share personal information except in the case of service providers, legal compliance or the sale of the business.
There are also valid concerns that private companies offering health services weakens Canada's universal health care and encourages a two-tier system. Not everyone has the means or desire to spend $600-plus on tests. At the moment, that limits customers to wellness and health fanatics rather than the general public. But knowing the stats on what's happening in your body − and what those stats mean − is one way you can start taking better control of your health.
Without seeing the numbers and some general recommendations from the folks at NiaHealth, any changes would have been largely guesswork. Still, it's a big spend for general feedback such as trying a Mediterranean diet, exercise and the value of vitamin D.
For anyone looking to get the benefits of blood work without breaking the bank, working with your doctor and requesting basic panels is still your best bet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR
Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR

Globe and Mail

time4 hours ago

  • Globe and Mail

Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR

Biochips Market, By Product Type (DNA Chips, Protein Chips, Lab-on-chip Tissue Arrays, Cell Arrays), By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) According to a recent report by Coherent Market Insights, Global Biochips market is estimated to be valued at USD 13.34 Bn in 2025 and is expected to reach USD 37.73 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2025 to 2032. Increasing application of biochips in the field of proteomics, genomics and drug discovery can drive the market growth. Extensive R&D activities in the field of healthcare and growing demand for point-of-care testing and diagnostics can also boost demand for biochips during the forecast period. Global Biochips Market Key Takeaways According to Coherent Market Insights (CMI), the global biochips market size is projected to grow at a robust CAGR of 16%, from USD 13.34 Bn in 2025 to USD 37.73 Bn by 2032. Based on product type, DNA chips segment is expected to account for over two-fifths of the global biochips market in 2025. By end user, biotechnology and pharmaceuticals segment will likely hold a market share of 35.1% by 2025. North America is anticipated to retain its dominance, holding a market share of nearly 2/5 in 2025. As per CMIs' new biochips market analysis, Asia Pacific is expected to experience fastest growth during the forecast period. Growing Demand for Personalized Medicine Boosting Market Growth Coherent Market Insights' latest biochips market research report highlights major factors driving industry growth. One such prominent growth factor is the increasing demand for personalized medicine. Biochips are a key enabling technology in personalized medicine. They enable rapid and accurate analysis of an individual's genetic and proteomic profiles. This supports pharmacogenomics, helps in creating tailored treatment plans, and facilitates targeted therapies. These capabilities are especially valuable in managing complex diseases such as cancer. Thus, growing interest in personalized medicine will continue to provide a strong impetus for the growth of biochips market in the coming years. High Cost of Biochips and Adoption of Alternative Technologies Limiting Market Growth The future biochips market outlook looks promising. However, high cost of bioships and associated equipment, along with growing usage of alternative technologies, remain a significant barrier to broader market growth. Biochips are quite expensive due to their complex manufacturing processes and the need for specialized instrumentation. This high cost limits their accessibility, particularly among small and mid-sized laboratories, thereby reducing overall biochips market demand. Many end users are turning to alternative technologies like immunoassays, qPCR, and next-generation sequencing (NGS) due to their accuracy and cost-efficiency. This trend may also negatively impact the biochips market growth in the coming years. Growing Adoption in Disease Diagnostics Creating Lucrative Growth Opportunities Biochips are being increasingly used in the diagnosis of cancer, genetic disorders, and infectious diseases due to their high accuracy and speed. Their rising adoption in disease diagnostics is expected to create lucrative growth opportunities for biochip manufacturers during the forecast period. Rising incidence of chronic and infectious diseases, such as COVID-19, is creating a strong need for rapid diagnostics. This is expected to drive demand for biochips, as they offer fast and multiplexed detection of pathogens, making them ideal for point-of-care testing. Get Up to 25% Discount on the US Tariff Impact Analysis Report: Impact of AI on the Biochips Market Artificial Intelligence (AI) is making a profound impact on the biochips market. It enhances data analysis, diagnostics, and personalized medicine. AI algorithms significantly improve the accuracy and speed of disease detection by rapidly interpreting complex biological data produced by biochips. This powerful combination accelerates drug discovery and enables real-time health monitoring. With ongoing advancements in AI, new applications and efficiencies are expected to emerge. This evolution is poised to propel the biochips market toward greater scalability and precision in delivering advanced healthcare solutions. Emerging Biochips Market Trends Growing trend of miniaturization is significantly impacting the biochips market value. Key manufacturers are focusing on developing compact biochips (e.g. lab-on-a-chip systems) with improved features for use in diagnostics, drug discovery, and personalized medicine. Expanding applications of biochips in drug discovery is expected to foster sales growth. Biochips are increasingly used in drug discovery processes, particularly for gene expression analysis, toxicity profiling, and target identification. These applications are crucial for accelerating pharmaceutical R&D, thereby driving market growth. There is a growing emphasis on studying genes and proteins to better understand disease mechanisms, identify potential therapeutic targets, and develop personalized medicine approaches. This will likely create a strong demand for biochips in high-throughput research. Shift toward point-of-care testing (POCT) is expected to create lucrative growth avenues for biochip companies. Portable biochips are being widely used in POCT devices for faster diagnostics at the patient's location. Ongoing advancements in biochip manufacturing will also support market expansion. Improvements in microfluidics, microarray technology, and semiconductor biochip development are significantly enhancing capabilities of biochips. Analyst's View ' The global biochips market is expected to record robust growth, owing to increasing incidence of chronic and infectious diseases, rising demand for personalized medicines, and advancements in biochip manufacturing,' said senior analyst Abhijeet Kale. Current Events and Their Impact on the Biochips Market Competitor Insights Key companies listed in biochips market report: - LinguaFlex - Inspire Medical Systems, Inc. - Medtronic - LivaNova PLC - SomnoMed - Nihon Kohden Corporation - Siesta Medical Inc. - ResMed - Koninklijke Philips N.V. - Somnowell - Nyxoah SA - Fisher & Paykel Healthcare Limited - VYAIRE - Natus Medical Incorporated - Nox Medical - Drive DeVilbiss International - CLEVELAND MEDICAL DEVICES INC. - Advanced Brain Monitoring, Inc. - CONTEC MEDICAL SYSTEMS CO., LTD Key Developments In January 2025, Coherent Corp launched its new pinhole array biochips. These biochips are specifically designed for medical diagnostics, with a strong focus on gene sequencing applications. In May 2025, Archer Materials Limited partnered with Paragraf Limited for Biochip development. This partnership is intended to help Archer advance its Biochip for at-home testing of chronic kidney disease. Market Segmentation By Product Type DNA Chips Cancer Diagnosis and Treatment Gene Expression SNP Genotyping Genomics Drug Discovery Agricultural Biotechnology Others Protein Chips Proteomics Expression Profiling Diagnostics HTS Others Lab-on-chip IVD & POC Others Tissue Arrays Cell Arrays By End User Biotechnology and Pharmaceutical Companies Academic & Research Institutes Hospitals and Diagnostic Centers Others About Us:Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Shah Email: Send Email Phone: + 12524771362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States Burlingame City: Burlingame State: California Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store